Veracyte stock trades at EUR 21.32 late Thursday

Published on 11/06/2026 at 01:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Veracyte stock reflects a company focused on cancer diagnostics. Investor events are scheduled for November 10, 18 and 19.

Diagnostics business and investor calendar

Veracyte develops diagnostic tests that support cancer diagnosis and treatment decisions.
The company has investor conferences scheduled for November 10, 18 and 19, 2026.

VCYT, US92337F1075, Illustration mit AI erstellt.

Veracyte stock traded at 21.32 euros on Lang & Schwarz at 11:00 p.m. CET on Thursday, November 5, 2026. The late-session quote provides the latest market reference for investors following the US diagnostics company.

Diagnostics focus shapes the investment case

Veracyte develops diagnostic tests intended to help clinicians guide patients through cancer diagnosis and treatment decisions. Its portfolio addresses thyroid, prostate, breast, bladder and lung cancers, as well as interstitial lung diseases, according to the Veracyte investor relations page.

Upcoming investor events

Veracyte lists the UBS Global Healthcare Conference for November 10, followed by the Jefferies Global Healthcare Conference on November 18 and the Stephens Annual Investment Conference on November 19. These events give investors scheduled opportunities to monitor management commentary and strategic priorities.

Investors can follow the real-time quote of Veracyte stock for subsequent trading updates.

US equities remain the broader market context for Veracyte stock; see the S&P 500 market coverage.

More developments are available in more news and analyses on Veracyte stock.